Skip to main navigation Skip to search Skip to main content

Consortium analysis of 7 candidate SNPs for ovarian cancer

  • Susan J. Ramus
  • , Robert A. Vierkant
  • , Sharon E. Johnatty
  • , Malcolm C. Pike
  • , David J. Van Den Berg
  • , Anna H. Wu
  • , Celeste Leigh Pearce
  • , Usha Menon
  • , Aleksandra Gentry-Maharaj
  • , Simon A. Gayther
  • , Richard A. DiCioccio
  • , Valerie McGuire
  • , Alice S. Whittemore
  • , Honglin Song
  • , Douglas F. Easton
  • , Paul D.P. Pharoah
  • , Montserrat Garcia-Closas
  • , Stephen Chanock
  • , Jolanta Lissowska
  • , Louise Brinton
  • Kathryn L. Terry, Daniel W. Cramer, Shelley S. Tworoger, Susan E. Hankinson, Andrew Berchuck, Patricia G. Moorman, Joellen M. Schildkraut, Julie M. Cunningham, Mark Liebow, Susanne Kru¨ger Kjaer, Estrid Hogdall, Claus Hogdall, Jan Blaakaer, Roberta B. Ness, Kirsten B. Moysich, Robert P. Edwards, Michael E. Carney, Galina Lurie, Marc T. Goodman, Shan Wang-Gohrke, Silke Kropp, Jenny Chang-Claude, Penelope M. Webb, Xiaoqing Chen, Jonathan Beesley, Georgia Chenevix-Trench, Ellen L. Goode, D. Bowtell, A. Green, A. DeFazio, D. Gertig, N. Traficante, S. Moore, J. Hung, S. Fereday, K. Harrap, T. Sadkowsky, A. Mellon, R. Robertson, T. Vanden Bergh, J. Maidens, K. Nattress, Y. E. Chiew, A. Stenlake, H. Sullivan, B. Alexander, P. Ashover, S. Brown, T. Corrish, L. Green, L. Jackman, K. Martin, B. Ranieri, J. White, V. Jayde, V. L. Bowes, P. Mamers, T. Schmidt, H. Shirley, S. Viduka, H. Tran, S. Bilic, L. Glavinas, A. Proietto, S. Braye, G. Otton, T. Bonaventura, J. Stewart, M. Friedlander, D. Bell, S. Baron-Hay, A. Ferrier, G. Gard, D. Nevell, B. Young, C. Camaris, R. Crouch, L. Edwards, N. Hacker, D. Marsden, G. Robertson, P. Beale, J. Beith, J. Carter, C. Dalrymple, A. Hamilton, R. Houghton, P. Russell, A. Brand, R. Jaworski, P. Harnett, G. Wain, A. Crandon, M. Cummings, K. Horwood, A. Obermair, D. Wyld, J. Nicklin, D. Papadimos, L. Perrin, B. Ward, M. Davy, C. Hall, T. Dodd, T. Healy, K. Pittman, D. Henderson, S. Hyde, J. Miller, J. Pierdes, P. Blomfield, D. Challis, R. McIntosh, A. Parker, B. Brown, R. Rome, D. Allen, P. Grant, R. Laurie, M. Robbie, D. Healy, T. Jobling, T. Maniolitas, J. McNealage, P. Rogers, B. Susil, A. Veitch, J. Constable, S. Ping Tong, I. Robinson, I. Simpson, K. Phillips, D. Rischin, P. Waring, M. Loughrey, N. O'Callaghan, Bill Murray, V. Billson, S. Galloway, J. Pyman, M. Quinn, I. Hammond, A. McCartney, Y. Leung, I. Haviv, D. Purdie, D. Whiteman, N. Zeps
  • University College London
  • Mayo Clinic Rochester, MN
  • Post Office Royal Brisbane Hospital
  • University of Southern California
  • Roswell Park Cancer Institute
  • Stanford University
  • University of Cambridge
  • National Institutes of Health
  • Maria Sklodowska-Curie Institute of Oncology
  • Brigham and Women’s Hospital
  • Harvard University
  • Duke University
  • Danish Cancer Society
  • University of Copenhagen
  • Aarhus University
  • University of Pittsburgh
  • University of Hawai'i at Mānoa
  • Ulm University
  • German Cancer Research Center
  • Peter Maccallum Cancer Centre
  • Queensland Institute of Medical Research
  • Westmead Hospital
  • University of Melbourne
  • Hunter New England Health
  • Royal Hospital for Women
  • Royal North Shore Hospital
  • Royal Prince Alfred Hospital
  • Royal Hobart Hospital
  • Monash Medical Centre
  • Western Australia Research Tissue Network
  • Newcastle Mater Misericordiae
  • Prince of Wales Hospital
  • UnitingCare Health
  • Sullivan Nicolaides Pathology
  • Mater Misericordiae Hospital
  • Royal Adelaide Hospital
  • Flinders Medical Centre
  • Mercy Hospital for Women
  • Queen Elizabeth Hospital Australia
  • Epworth HealthCare
  • Royal Women's Hospital
  • King Edward Memorial Hospital for Women

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

The Ovarian Cancer Association Consortium selected 7 candidate single nucleotide polymorphisms (SNPs), for which there is evidence from previous studies of an association with variation in ovarian cancer or breast cancer risks. The SNPs selected for analysis were F31I (rs2273535) in AURKA, N372H (rs144848) in BRCA2, rs2854344 in intron 17 of RB1, rs2811712 5′ flanking CDKN2A, rs523349 in the 3′ UTR of SRD5A2, D302H (rs1045485) in CASP8 and L10P (rs1982073) in TGFB1. Fourteen studies genotyped 4,624 invasive epithelial ovarian cancer cases and 8,113 controls of white non-Hispanic origin. A marginally significant association was found for RB1 when all studies were included [ordinal odds ratio (OR) 0.88 (95% confidence interval (CI) 0.79-1.00) p = 0.041 and dominant OR 0.87 (95% CI 0.76-0.98) p = 0.025]; when the studies that originally suggested an association were excluded, the result was suggestive although no longer statistically significant (ordinal OR 0.92, 95% CI 0.79-1.06). This SNP has also been shown to have an association with decreased risk in breast cancer. There was a suggestion of an association for AURKA, when one study that caused significant study heterogeneity was excluded [ordinal OR 1.10 (95% CI 1.01-1.20) p = 0.027; dominant OR 1.12 (95% CI 1.01-1.24) p = 0.03]. The other 5 SNPs in BRCA2, CDKN2A, SRD5A2, CASP8 and TGFB1 showed no association with ovarian cancer risk; given the large sample size, these results can also be considered to be informative. These null results for SNPs identified from relatively large initial studies shows the importance of replicating associations by a consortium approach.

Original languageEnglish
Pages (from-to)380-388
Number of pages9
JournalInternational Journal of Cancer
Volume123
Issue number2
DOIs
StatePublished - Jul 15 2008

Keywords

  • Association study
  • Neoplasms
  • Ovarian cancer
  • Replication
  • Single nucleotide polymorphism

Fingerprint

Dive into the research topics of 'Consortium analysis of 7 candidate SNPs for ovarian cancer'. Together they form a unique fingerprint.

Cite this